PFE has four anti-angio compounds in early development for eye disease: three of its own compounds and one acquired from Angiosyn (#msg-5169089). This is in addition to PFE’s participation in Macugen.
Source: PFE webcast in progress.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”